Mayo Test Catalog, (Sorted By Test Name) - Mayo Medical ...

HL15O
60348
HLA57
89346
syndrome and toxic epidermal necrolysis when administered carbamazepine, phenytoin, or fosphenytoin
therapy
Interpretation: Positivity for human leukocyte antigen (HLA)-B*1502 confers increased risk for
hypersensitivity to carbamazepine, phenytoin, or fosphenytoin.
Reference Values:
An interpretive report will be provided.
Clinical References: 1. Man CB, Kwan P, Baum L, et al: Association between HLA-B*1502
allele and antiepileptic drug-induced cutaneous reactions in Han Chinese. Epilepsia 2007;40:1015-1018
2. Chung WH, Hung SL, Hong HS, et al: Medical genetics: a marker for Stevens-Johnson syndrome.
Nature 2004;428:486 3. Hung SL, Chung WH, Jee SH, et al: Genetic susceptibility to
carbamazepine-induced cutaneous adverse drug reaction. Pharmacogenet Genomics 2006;16:297-306 4.
Cox ST, McWhinnie AJ, Robinson J, et al: Cloning and sequencing full-length HLA-B and -C genes.
Tissue Antigens 2003;61:20-48 5. Hung, Shuen-Iu. Chung, Wen-Hung. Liu, Zhi-Sheng. Chen et al:
Common risk allele in aromatic antiepileptic-drug induced Stevens-Johnson syndrome and toxic
epidermal necrolysis in Han Chinese. Pharmacogenomics. 2010;11:349-356
HLA-B 1502 Genotype, Carbamazepine Hypersensitivity,
Saliva
Clinical Information: Clinical studies have demonstrated associations between some HLA
genotypes and drug-induced adverse skin reactions. The presence of the HLA-B*1502 allele increases
the risk of developing toxic epidermal necrolysis (TEN) or Stevens-Johnson syndrome (SJS), a milder
form of TEN. The frequency of the HLA-B*1502 allele varies throughout Asia: 10% to 15% frequency
in Chinese, 2% to 4% frequency in Southeast Asians, including Indians, and